

Sterile Injectable Product And CMO Volume



ISR asked respondents responsible for sterile injectable manufacturing outsourcing about the amount and type of outsourced compounds they have in development, in marketing, or foresee themselves having in five years. Overall, respondents anticipate having one additional small molecule sterile injectable product on the market in the next five years. Rates were on par for marketed biologic products, which are also predicted to increase by one product over the next five years.


"About how many compounds does your company have that will be sterile injectable formulations?"

"What percentage of your compounds with sterile injectable formulations are small molecule vs biologic?"


"Please allocate the proportion of [small molecule/biologic] compounds with sterile injectable formulations that are manufactured in-house versus outsourced."

"How many CMOs does your company work with to meet your sterile injectable drug manufacturing needs?"

Sterile Injectable Outsourcing Volume: Development



Sterile Injectable Outsourcing Volume: Marketed



Sterile Injectable Outsourcing Volume: In 5 Years

